• PDF: Delivered by email usually within 12 to 48 UK business hours.

Urological Disorders Therapeutics to 2016
Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

  • Publication Date:August 2010
  • Publisher:GBI Research
  • Product Type: Report
  • Pages:125

Urological Disorders Therapeutics to 2016 Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Summary

GBI Research's Therapeutic Analysis report, 'Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets', provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. GBI Research finds that the urological disorders market will continue to grow moderately, largely due to increase in aging population and increase in awareness of indications such as UI, BPH and UTI. The prime reason for slow growth of the market will be a series of patent expiries of the top selling blockbusters across all the markets. Particularly in BPH, the entry of generics coupled with the patent expirations of Flomax, Uroxatral (in US) and Avodart, three of the best selling drugs in the BPH market, is expected to pull down the market in terms of value in the future. However, the patent expiries will not result in significant market value loss due to the low price differential between branded and generics.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope:

  • Annualized market data for the urological disorders market from 2001 to 2009, forecast forward to 2016.
  • Analysis of the leading therapeutic segments, including Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI).
  • Analysis of the urological disorders market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.
  • Market characterization of the urological disorders market, including market size, annual cost of therapy and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of drug development.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc, Novexel SA, Eli Lilly and Company, GSK, Sanofi-- Aventis, Johnson and Johnson and Protox Therapeutics, Inc.
  • Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global urological disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Global Urological Disorders Market: Introduction
    • 2.1 GBI Research Report Guidance
  • 3 Global Urological Disorders Market: Market Overview
    • 3.1 Introduction
    • 3.2 Revenue Forecasts for the Global Urological Disorders Market
      • 3.2.1 Sales Value
      • 3.2.2 Annual Cost of Therapy
      • 3.2.3 Treatment Usage Patterns
      • 3.2.4 Generics' Share in the Global Urological Disorders Market
    • 3.3 Urological Disorders Market Drivers
      • 3.3.1 Steady Increase in the UI and BPH Prevalence Population
      • 3.3.2 Rapid Uptake of Branded Products due to Better Efficacy in BPH
      • 3.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable
    • 3.4 Urological Disorders Market Restraints
      • 3.4.1 Unwillingness to Seek Medical Help for UI
      • 3.4.2 Patent Expiries of Major Blockbusters Including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenues
      • 3.4.3 Non Pharmacological Therapy Recommended for UI and BPH
  • 4 Global Urological Disorders Market: Therapeutic Landscape
    • 4.1 Benign Prostatic Hyperplasia Market
      • 4.1.1 Introduction
      • 4.1.2 Sales Value
      • 4.1.3 Annual Cost of Therapy
      • 4.1.4 Treatment Usage Patterns
      • 4.1.5 Market Share by Geography
      • 4.1.6 Generics' Share of the Global BPH Market
    • 4.2 Urinary Incontinence (UI) Market
      • 4.2.1 Introduction
      • 4.2.2 Sales Value
      • 4.2.3 Annual Cost of Therapy
      • 4.2.4 Treatment Usage Patterns
      • 4.2.5 Market Share by Geography
      • 4.2.6 Generics' Share in the Global UI Market
    • 4.3 Urinary Tract Infections Market
      • 4.3.1 Introduction
      • 4.3.2 Sales Value
      • 4.3.3 Annual Cost of Therapy
      • 4.3.4 Treatment Usage Patterns
      • 4.3.5 Market Share by Geography
      • 4.3.6 Generics' Share of the Global UTI Market
  • 5 Global Urological Disorders Market: Geographical Landscape
    • 5.1 Geographical Break-up
    • 5.2 The US
      • 5.2.1 Sales Value
      • 5.2.2 Annual Cost of Therapy
      • 5.2.3 Treatment Usage Patterns
    • 5.3 Top Five Countries in Europe
      • 5.3.1 Sales Value
      • 5.3.2 Annual Cost of Therapy
      • 5.3.3 Treatment Usage Patterns
    • 5.4 Japan
      • 5.4.1 Sales Value
      • 5.4.2 Annual Cost of Therapy
      • 5.4.3 Treatment Usage Patterns
  • 6 Global Urological Disorders Market: Pipeline Analysis
    • 6.1 Introduction
      • 6.1.1 Research and Development Pipeline – UI
      • 6.1.2 Research and Development Pipeline – BPH
      • 6.1.3 Research and Development Pipeline – UTI
    • 6.2 Profiles of Key Late-Stage Drugs in the Urological Disorders Market
      • 6.2.1 Botulinum Toxin A
      • 6.2.2 YM178
      • 6.2.3 NX-1207
      • 6.2.4 PRX302
      • 6.2.5 NXL104/ceftazidime
  • 7 Global Urological Disorders Market: Competitive Landscape
    • 7.1 Market Share Analysis: Urological Disorders
    • 7.2 Competitive Profiling
      • 7.2.1 Astellas Pharma
      • 7.2.2 Johnson and Johnson (J&J)
      • 7.2.3 Pfizer
      • 7.2.4 GlaxoSmithKilne (GSK)
      • 7.2.5 Sanofi-Aventis
  • 8 Global Urological Disorders Market: Strategic Consolidations
    • 8.1 Overview
      • 8.1.1 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009
      • 8.1.2 Actavis Group Acquires Floxapen from GlaxoSmithKline in May 2007
      • 8.1.3 Biofusion Acquires Minority Stake in Muscagen in November 2006
      • 8.1.4 Eli Lilly Reacquires Rights to Yentreve from Boehringer Ingelheim in February 2006
      • 8.1.5 Odyssey Pharmaceuticals Sells SANCTURA to Esprit Pharma in May 2005
      • 8.1.6 Ardana Bioscience Acquires Rights to Teverelix from AEterna Zentaris in April 2004
    • 8.2 R&D Licensing Agreements
      • 8.2.1 Deals by Indication
      • 8.2.2 Deals by Phase
      • 8.2.3 Deals by Geography
      • 8.2.4 Deals by Licensing Type
      • 8.2.5 Deals by Value ($)
      • 8.2.6 Phase I
      • 8.2.7 Phase II
      • 8.2.8 Approved
  • 9 Global Urological Disorders Market: Appendix
    • 9.1 Market Definitions
    • 9.2 Abbreviations
    • 9.3 Research Methodology
      • 9.3.1 Coverage
      • 9.3.2 Secondary Research
      • 9.3.3 Primary Research
      • 9.3.4 Forecasts
      • 9.3.5 Expert Panel Validation
    • 9.4 Contact Us
    • 9.5 Disclaimer
    • 9.6 Sources
  • List of Tables
    • Table 1: Urological Disorders Market, Global, Sales Value ($bn), 2001–2009
    • Table 2: Urological Disorders Market, Global, Sales Value ($bn), 2009–2016
    • Table 3: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2001–2009
    • Table 4: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2009–2016
    • Table 5: Urological Disorders Market, Global, Treatment Usage Patterns (million), 2001–2009
    • Table 6: Urological Disorders Market, Global, Treatment Usage Patterns (million), 2009–2016
    • Table 7: Urological Disorders Market, Global, Branded Vs Generic Drugs ($bn), 2001–2009
    • Table 8: Urological Disorders Market, Global, Branded Vs Generic Drugs ($bn), 2009–2016
    • Table 9: Urological Disorders Market, Global, BPH Sales Value ($bn), 2001–2009
    • Table 10: Urological Disorders Market, Global, BPH Sales Value ($bn), 2009–2016
    • Table 11: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2001–2009
    • Table 12: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2009–2016
    • Table 13: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2001–2009
    • Table 14: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2009–2016
    • Table 15: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2001–2009
    • Table 16: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2009–2016
    • Table 17: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2001–2009
    • Table 18: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2009–2016
    • Table 19: Urological Disorders Market, Global, UI Sales Value ($bn), 2001–2009
    • Table 20: Urological Disorders Market, Global, UI Sales Value ($bn), 2009–2016
    • Table 21: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2001–2009
    • Table 22: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2009–2016
    • Table 23: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2001–2009
    • Table 24: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2009–2016
    • Table 25: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2001–2009
    • Table 26: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2009–2016
    • Table 27: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2001–2009
    • Table 28: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2009–2016
    • Table 29: Urological Disorders Market, Global, UTI Sales Value ($bn), 2001–2009
    • Table 30: Urological Disorders Market, Global, UTI Sales Value ($bn), 2009–2016
    • Table 31: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2001–2009
    • Table 32: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2009–2016
    • Table 33: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2001–2009
    • Table 34: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2009–2016
    • Table 35: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2001–2009
    • Table 36: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2009–2016
    • Table 37: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2001–2009
    • Table 38: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2009–2016
    • Table 39: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2001–2009
    • Table 40: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2009–2016
    • Table 41: Urological Disorders Market, US, Sales Value ($bn), 2001–2009
    • Table 42: Urological Disorders Market, US, Sales Value ($bn), 2009–2016
    • Table 43: Urological Disorders Market, US, Annual Cost of Therapy ($), 2001–2009
    • Table 44: Urological Disorders Market, US, Annual Cost of Therapy ($), 2009–2016
    • Table 45: Urological Disorders Market, US, Treatment Usage Patterns (million), 2001–2009
    • Table 46: Urological Disorders Market, US, Treatment Usage Patterns (million), 2009–2016
    • Table 47: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2009
    • Table 48: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2009–2016
    • Table 49: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2009
    • Table 50: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016
    • Table 51: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2001–2009
    • Table 52: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2009–2016
    • Table 53: Urological Disorders Market, Japan, Sales Value ($bn), 2001–2009
    • Table 54: Urological Disorders Market, Japan, Sales Value ($bn), 2009–2016
    • Table 55: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2009
    • Table 56: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2009–2016
    • Table 57: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2009
    • Table 58: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2009–2016
    • Table 59: Urological Disorders Market, Global, R&D Pipeline by Phase in UI Market, AUG 2010
    • Table 60: Urological Disorders Market, Global, R&D Pipeline by Phase in BPH Market, AUG 2010
    • Table 61: Urological Disorders Market, Global, R&D Pipeline by Phase in UTI Market, AUG 2010
    • Table 62: Urological Disorders Market, Global, Major M&A Deals, 2004-2009
    • Table 63: Urological Disorders Market, Global, Licensing Agreements for Drugs in Phase I Stage, 2004
    • Table 64: Urological Disorders Market, Global, Licensing Agreements for Drugs in Phase II Stage, 2004–2010
    • Table 65: Urological Disorders Market, Global, Licensing Agreements for Approved Drugs, 2008–2010
  • List of Figures
    • Figure 1: Urological Disorders Market, Global, Drivers and Restraints, 2009
    • Figure 2: Urological Disorders Market, Global, Sales Value ($bn), 2001–2016
    • Figure 3: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2001–2016
    • Figure 4: Urological Disorders Market, Global, Therapeutic Usage Patterns (million), 2001–2016
    • Figure 5: Urological Disorders Market, Global, Diseased Population (million), 2001–2016
    • Figure 6: Urological Disorders Market, Global, Treatment Seeking Population (million), 2001–2016
    • Figure 7: Urological Disorders Market, Global, Diagnosis Population (million), 2001–2016
    • Figure 8: Urological Disorders Market, Global, Prescription Population (million), 2001–2016
    • Figure 9: Urological Disorders Market, Global, Branded Vs Generics ($bn), 2001–2016
    • Figure 10: Urological Disorders Market, Global, Market Indicators, 2009
    • Figure 11: Urological Disorders Market, Global, BPH Sales Value ($bn), 2001–2016
    • Figure 12: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2001–2016
    • Figure 13: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2001–2016
    • Figure 14: Urological Disorders Market, Global, BPH Diseased Population (million), 2001–2016
    • Figure 15: Urological Disorders Market, Global, BPH Treatment Seeking Population (million), 2001–2016
    • Figure 16: Urological Disorders Market, Global, BPH Diagnosis Population (million), 2001–2016
    • Figure 17: Urological Disorders Market, Global, BPH Prescription Population (million), 2001–2016
    • Figure 18: Urological Disorders Market, Global, BPH Market Segmentation by Geography (%), 2009 and 2016
    • Figure 19: Urological Disorders Market, Global, BPH Market in the Top Five Countries in Europe (%), 2009 and 2016
    • Figure 20: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2001–2016
    • Figure 21: Urological Disorders Market, Global, BPH Market, Geography Benchmarking, 2009
    • Figure 22: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2001–2016
    • Figure 23: Urological Disorders Market, Global, BPH Market, Generics Share (%), 2009 and 2016
    • Figure 24: Urological Disorders Market, Global, UI Sales Value ($bn), 2001–2016
    • Figure 25: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2001–2016
    • Figure 26: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2001–2016
    • Figure 27:Urological Disorders Market, Global, UI Diseased Population (million), 2001–2016
    • Figure 28:Urological Disorders Market, Global, UI Treatment Seeking Population (million), 2001–2016
    • Figure 29:Urological Disorders Market, Global, UI Diagnosis Population (million), 2001–2016
    • Figure 30: Urological Disorders Market, Global, UI Prescription Population (million), 2001–2016
    • Figure 31: Urological Disorders Market, Global, UI Market Segmentation by Geography (%), 2009 and 2016
    • Figure 32: Urological Disorders Market, Global, UI Market in the Top Five Countries in Europe (%), 2009 and 2016
    • Figure 33: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2001–2016
    • Figure 34: Urological Disorders Market, Global, UI Market, Geography Benchmarking, 2009
    • Figure 35: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2001–2016
    • Figure 36: Urological Disorders Market, Global, UI Market, Generics Share (%), 2009 and 2016
    • Figure 37: Urological Disorders Market, Global, UTI Sales Value ($bn), 2001–2016
    • Figure 38: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2001–2016
    • Figure 39: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2001–2016
    • Figure 40: Urological Disorders Market, Global, UTI Diseased Population (million), 2001–2016
    • Figure 41: Urological Disorders Market, Global, UTI Treatment Seeking Population (million), 2001–2016
    • Figure 42: Urological Disorders Market, Global, UTI Diagnosis Population (million), 2001–2016
    • Figure 43: Urological Disorders Market, Global, UTI Prescription Population (millions), 2001–2016
    • Figure 44: Urological Disorders Market, Global, UTI Market Segmentation by Geography (%), 2009 and 2016
    • Figure 45: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2001–2016
    • Figure 46: Urological Disorders Market, Global, UTI Market, Geography Benchmarking, 2009
    • Figure 47: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2001–2016
    • Figure 48: Urological Disorders Market, Global, UTI Market, Generics Share (%), 2009 and 2016
    • Figure 49: Urological Disorders Market, Global, Market Share by Geography (%), 2009 and 2016
    • Figure 50: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2001–2016
    • Figure 51: Urological Disorders Market, Global, Geography Benchmarking, 2009 and 2016
    • Figure 52: Urological Disorders Market, US, Sales Value ($bn), 2001–2016
    • Figure 53: Urological Disorders Market, US, Annual Cost of Therapy ($), 2001–2016
    • Figure 54: Urological Disorders Market, US, Treatment Usage Patterns (million), 2001–2016
    • Figure 55: Urological Disorders Market, US, Diseased Population (million), 2001–2016
    • Figure 56: Urological Disorders Market, US, Treatment Seeking Population (million), 2001–2016
    • Figure 57: Urological Disorders Market, US, Diagnosis Population (million), 2001–2016
    • Figure 58: Urological Disorders Market, US, Prescription Population (million), 2001–2016
    • Figure 59: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2016
    • Figure 60: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2016
    • Figure 61: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2001–2016
    • Figure 62: Urological Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2001–2016
    • Figure 63: Urological Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2001–2016
    • Figure 64: Urological Disorders Market, Top Five Countries in Europe, Diagnosis Population (million), 2001–2016
    • Figure 65: Urological Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2001–2016
    • Figure 66: Urological Disorders Market, Japan, Sales Value ($bn), 2001–2016
    • Figure 67: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2016
    • Figure 68: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2016
    • Figure 69: Urological Disorders Market, Japan, Diseased Population (million), 2001–2016
    • Figure 70: Urological Disorders Market, Japan, Treatment Seeking Population (million), 2001–2016
    • Figure 71: Urological Disorders Market, Japan, Diagnosed Population (million), 2001–2016
    • Figure 72: Urological Disorders Market, Japan, Prescription Population (million), 2001–2016
    • Figure 73: Urological Disorders Market, Global, R&D Pipeline by Indication (%), AUG 2010
    • Figure 74: Urological Disorders Market, Global, R&D Pipeline by Phase (%), AUG 2010
    • Figure 75: Urological Disorders Market, Global, R&D Pipeline by Phase in UI Market (%), AUG 2010
    • Figure 76: Urological Disorders Market, Global, R&D Pipeline by Phase in BPH Market (%), AUG 2010
    • Figure 77: Urological Disorders Market, Global, R&D Pipeline by Phase in UTI Market (%), AUG 2010
    • Figure 78: Urological Disorders Market, Global, Market Share of Top Manufacturers (%), 2009
    • Figure 79: Urological Disorders Market, Global, Revenue of Top Five Players ($m), 2007–2009
    • Figure 80: Urological Disorders Market, Global, Competitive Analysis of Top Five Players, Market Share and CAGR (%), 2007–2009
    • Figure 81: Urological Disorders Market, Global, SWOT- Astellas Pharma, 2010
    • Figure 82: Urological Disorders Market, Global, SWOT- Johnson & Johnson, 2010
    • Figure 83: Urological Disorders Market, Global, SWOT- Pfizer, 2010
    • Figure 84: Urological Disorders Market, Global, SWOT- GlaxoSmithKline, 2010
    • Figure 85: Urological Disorders Market, Global, SWOT- Sanofi-Aventis, 2010
    • Figure 86: Urological Disorders Market, Global, M&A Deals by Indication (%), 2009
    • Figure 87: Urological Disorders Market, Global, Major Licensing Agreements By Indication (%), 2004–2010
    • Figure 88: Urological Disorders Market, Global, Major Licensing Agreements By Phase (%), 2005–2010
    • Figure 89: Urological Disorders Market, Global, Major Licensing Agreements By Geography (%), 2004–2010
    • Figure 90: Urological Disorders Market, Global, Major Licensing Agreements By Licensing Type (%), 2004–2010
    • Figure 91: Urological Disorders Market, Global, Major Licensing Agreements By Deal Value (%), 2004–2010
    • Figure 92: GBI Research Market Forecasting Model
+44 20 8816 8548

Ask a question about Urological Disorders Therapeutics to 2016

Enter the characters you see in the picture below
Captcha